Advertisement
Table 7 Prophylaxis with danazol and comparison of location-related symptoms between women and men in 2012
| Location of attacks | All | Women | no prophylaxis vs. Danazol | Men | no prophylaxis vs. Danazol | women vs. men | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| All | No prophylaxis | Danazol | p-values | All | No prophylaxis | Danazol | p-values | p-values | ||
| 104 | 57 | 31 | 13 | 47 | 28 | 13 | ||||
| abdomen | 68 (65 %) | 40 (70 %) | 24 (77 %) | 6 (46 %) | p = 0.042 | 28 (59 %) | 15 (53 %) | 9 (69 %) | p = 0.344 | p = 0.063 |
| extremities | 61 (59 %) | 34 (60 %) | 20 (64 %) | 5 (38 %) | p = 0.111 | 27 (57 %) | 14 (50 %) | 8 (61 %) | p = 0.491 | p = 0.157 |
| trunk | 22 (21 %) | 15 (26 %) | 8 (26 %) | 3 (10 %) | p = 0.849* | 7 (15 %) | 4 (14 %) | 0 | p = 0.288* | p = 0.523* |
| face | 22 (21 %) | 14 (24 %) | 8 (26 %) | 2 (6 %) | p = 0.697* | 8 (17 %) | 4 (14 %) | 1 (8 %) | p = 0.486** | p = 0.709** |
| genitals | 22 (21 %) | 11 (19 %) | 8 (26 %) | 1 (3 %) | p = 0.242* | 11 (23 %) | 5 (18 %) | 3 (23 %) | p = 0.692* | p = 0.586* |
| headache | 16 (15 %) | 11 (19 %) | 4 (13 %) | 3 (10 %) | p = 0.404* | 5 (11 %) | 4 (14 %) | 0 | p = 0.288* | p = 0.509* |
| larynx | 16 (15 %) | 9 (16 %) | 6 (19 %) | 1 (3 %) | p = 0.654 | 7 (15 %) | 4 (14 %) | 1 (8 %) | p = 0.486** | p = 0.700** |
